Effects of triamcinolone acetonide injections with and without preservative
- Dr J Jonas, Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Jost.Jonas{at}augen.ma.uni-heidelberg.de
Though the vitreous body was long considered to be “untouchable”, it was Robert Machemer who taught the ophthalmic community how to surgically interact with the vitreous and how to perform direct surgery on the retina. Robert Machemer, along with others like Gholam Peyman, also proposed using the vitreous cavity as a reservoir for drugs to directly treat intraocular diseases.1 2 Robert Machemer and colleagues thought in particular on the use of intravitreal triamcinolone acetonide for therapy of proliferative vitreoretinopathy.1 3 As a result of Machener’s suggestion, intravitreal triamcinolone has been used to treat a considerable number of intraocular proliferative, oedematous and neovascular diseases such as proliferative diabetic retinopathy,4 diffuse diabetic macular oedema,5–8 branch and central retinal vein occlusions,9–11 neovascular glaucoma,12 exudative age-related macular degeneration,13–19 presumed ocular histoplasmosis syndrome, chronic pre-phthisical ocular hypotony, chronic uveitis,19 persistent pseudophakic cystoid macular oedema, sympathetic ophthalmia, radiation-induced macular oedema, immunological corneal graft reaction, perifoveal telangiectasia, ischaemic ophthalmopathy, extensive exudative retinal detachment, and other disorders such as cystoid macular …
